100 related articles for article (PubMed ID: 18449185)
1. Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs.
Merlo-Pich E; Gomeni R
Clin Pharmacol Ther; 2008 Sep; 84(3):378-84. PubMed ID: 18449185
[TBL] [Abstract][Full Text] [Related]
2. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
3. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
[TBL] [Abstract][Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
7. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.
Merlo-Pich E; Alexander RC; Fava M; Gomeni R
Clin Pharmacol Ther; 2010 Nov; 88(5):634-42. PubMed ID: 20861834
[TBL] [Abstract][Full Text] [Related]
8. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
9. Simple options for improving signal detection in antidepressant clinical trials.
Mallinckrodt CH; Meyers AL; Prakash A; Faries DE; Detke MJ
Psychopharmacol Bull; 2007; 40(2):101-14. PubMed ID: 17514189
[TBL] [Abstract][Full Text] [Related]
10. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
11. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD).
Sackeim HA; Roose SP; Lavori PW
Biol Psychiatry; 2006 Mar; 59(6):483-92. PubMed ID: 16517241
[TBL] [Abstract][Full Text] [Related]
12. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
[TBL] [Abstract][Full Text] [Related]
13. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
[TBL] [Abstract][Full Text] [Related]
16. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
17. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
18. Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
Argyropoulos SV; Hicks JA; Nash JR; Bell CJ; Rich AS; Nutt DJ; Wilson S
J Sleep Res; 2009 Sep; 18(3):342-8. PubMed ID: 19549078
[TBL] [Abstract][Full Text] [Related]
19. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
[TBL] [Abstract][Full Text] [Related]
20. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder.
Ballesteros J; Callado LF; Gutiérrez M
J Clin Psychopharmacol; 2007 Apr; 27(2):219-21. PubMed ID: 17414254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
